Ultragenyx Total Liabilities
Ultragenyx total liabilities. Based on the latest financial reports, Ultragenyx (RARE) has total liabilities worth $1.55 Billion USD as of June 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check how resilient are Ultragenyx's assets to evaluate the company's liquid asset resilience ratio.
Total Liabilities of Ultragenyx (2011–2025)
Total liabilities of Ultragenyx from 2011 to 2025. This chart illustrates how Ultragenyx's total liabilities have evolved over time, based on quarterly financial data. Explore Ultragenyx (RARE) investment intensity to see how much of total assets are deployed in long-term investments.
Ultragenyx Competitors by Total Liabilities
The table below lists competitors of Ultragenyx ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Daqo New Energy Corp ADR
NYSE:DQ
|
USA | $449.58 Million |
|
Baoding Lucky Innovative Materials Co Ltd
SHE:300446
|
China | CN¥4.71 Billion |
|
Vestjysk Bank A/S
CO:VJBA
|
Denmark | Dkr43.37 Billion |
|
Eastern Communications Co Ltd A
SHG:600776
|
China | CN¥944.95 Million |
|
Concord Biotech Limited
NSE:CONCORDBIO
|
India | Rs1.96 Billion |
|
Absci Corp
NASDAQ:ABSI
|
USA | $22.79 Million |
|
Shanghai DaZhong Public Utilities Group Co Ltd
SHG:600635
|
China | CN¥12.52 Billion |
|
DL E&C Co Ltd
KO:375500
|
Korea | ₩4.43 Trillion |
Liability Composition Analysis (2011–2025)
This chart breaks down Ultragenyx's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see RARE current and non-current assets.
Liquidity & Leverage Metrics
Ultragenyx Total Liabilities Ratios Explained
Ultragenyx total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.73 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | -5.32 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 1.22 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Ultragenyx's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Ultragenyx (2011–2025)
The table below shows the annual total liabilities of Ultragenyx from 2011 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $1.60 Billion | +29.31% |
| 2024-12-31 | $1.24 Billion | +2.10% |
| 2023-12-31 | $1.22 Billion | +1.90% |
| 2022-12-31 | $1.19 Billion | +98.88% |
| 2021-12-31 | $599.84 Million | -0.88% |
| 2020-12-31 | $605.18 Million | +25.63% |
| 2019-12-31 | $481.73 Million | +335.37% |
| 2018-12-31 | $110.65 Million | +3.12% |
| 2017-12-31 | $107.30 Million | +60.98% |
| 2016-12-31 | $66.65 Million | +134.04% |
| 2015-12-31 | $28.48 Million | +118.70% |
| 2014-12-31 | $13.02 Million | +36.50% |
| 2013-12-31 | $9.54 Million | +139.94% |
| 2012-12-31 | $3.98 Million | +167.56% |
| 2011-12-31 | $1.49 Million | -- |
About Ultragenyx
Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Europe, the Middle East, Africa, and the Asia-Pacific. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth fac… Read more